Similar articles

• Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.

  Ferretti G, Felici A, Papaldo P, Carlini P, Fabi A, Cognetti F. Ferretti G, et al. Oncologist. 2006 May;11(5):533; author reply 534. doi: 10.1634/theoncologist.11-5-533. Oncologist. 2006. PMID: 16720857 No abstract available.
• Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.

  [No authors listed] [No authors listed] Oncology (Williston Park). 2005 Jun;19(7):851, 862. Oncology (Williston Park). 2005. PMID: 16053034 No abstract available.
• Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.

  Altundag K, Baptista MZ. Altundag K, et al. Breast J. 2006 Sep-Oct;12(5):497-8. doi: 10.1111/j.1075-122X.2006.00314.x. Breast J. 2006. PMID: 16958977 No abstract available.
• Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

  Yaal-Hahoshen N, Safra T. Yaal-Hahoshen N, et al. Isr Med Assoc J. 2006 Jun;8(6):416-21. Isr Med Assoc J. 2006. PMID: 16833172 Review. No abstract available.
• [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].

  Wang LP, Shen KW, Shen ZZ. Wang LP, et al. Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):241-3. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 16875618 Review. Chinese. No abstract available.